ATE147385T1 - Chinuclidin derivat als substanz p antagonist - Google Patents

Chinuclidin derivat als substanz p antagonist

Info

Publication number: ATE147385T1
Authority: AT; Austria
Prior art keywords: pct; substance; antagonist; quinuclidine derivative; date
Prior art date: 1992-11-12

Application number

AT93917176T

Other languages

English (en)

Inventor

Fumitaka Ito

Hiroshi Kondo

Masami Nakane

Kaoru Shimada

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-11-12

Filing date

1993-07-19

Publication date

1997-01-15

1993-07-19 Application filed by Pfizer filed Critical Pfizer

1997-01-15 Application granted granted Critical

1997-01-15 Publication of ATE147385T1 publication Critical patent/ATE147385T1/de

Links

UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 title abstract 2
239000003890 substance P antagonist Substances 0.000 title abstract 2
PKOQGZGCLCOZTR-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxy-5-propylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCCC1=CC=C(OC)C(CN[C@@H]2[C@@H](N3CCC2CC3)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 PKOQGZGCLCOZTR-CONSDPRKSA-N 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

AT93917176T 1992-11-12 1993-07-19 Chinuclidin derivat als substanz p antagonist ATE147385T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US97524492A	1992-11-12	1992-11-12

Publications (1)

Publication Number	Publication Date
ATE147385T1 true ATE147385T1 (de)	1997-01-15

Family

ID=25522825

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93917176T ATE147385T1 (de)	1992-11-12	1993-07-19	Chinuclidin derivat als substanz p antagonist

Country Status (19)

Country	Link
US (1)	US5886009A (de)
EP (1)	EP0668863B1 (de)
JP (1)	JP2668164B2 (de)
KR (1)	KR950704311A (de)
CN (1)	CN1034732C (de)
AT (1)	ATE147385T1 (de)
AU (1)	AU676489B2 (de)
CA (1)	CA2149242C (de)
DE (1)	DE69307340T2 (de)
DK (1)	DK0668863T3 (de)
ES (1)	ES2096312T3 (de)
FI (1)	FI934983A7 (de)
GR (1)	GR3022459T3 (de)
IL (1)	IL107495A (de)
MX (1)	MX9307062A (de)
MY (1)	MY130145A (de)
NZ (1)	NZ254604A (de)
WO (1)	WO1994011368A1 (de)
ZA (1)	ZA938421B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6387925B1 (en) *	1999-06-01	2002-05-14	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) *	1999-06-22	2001-07-17	Pfizer Inc.	Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
DE10001785A1 (de) *	2000-01-18	2001-07-19	Boehringer Ingelheim Pharma	NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms
KR100821410B1 (ko)	2000-07-11	2008-04-10	에이엠알 테크놀로지, 인크.	4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
US6861526B2 (en) *	2002-10-16	2005-03-01	Pfizer Inc.	Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
US7671072B2 (en) *	2003-11-26	2010-03-02	Pfizer Inc.	Aminopyrazole derivatives as GSK-3 inhibitors
JP5021318B2 (ja) *	2004-01-30	2012-09-05	ファイザー・プロダクツ・インク	β−シクロデキストリンを液体投薬形態に用いて多用量製剤を達成するための抗菌性防腐剤
NZ552397A (en)	2004-07-15	2011-04-29	Amr Technology Inc	Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es)	2005-05-17	2012-06-13	Merck Sharp & Dohme Ltd.	Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko)	2005-07-15	2016-02-18	알바니 몰레큘라 리써치, 인크.	아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (de)	2005-09-29	2012-05-30	Merck Sharp & Dohme Corp.	Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
US8173629B2 (en)	2006-09-22	2012-05-08	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh)	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
JP4611444B2 (ja)	2007-01-10	2011-01-12	イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー	ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5319518B2 (ja)	2007-04-02	2013-10-16	Ｍｓｄ株式会社	インドールジオン誘導体
AU2008269154B2 (en)	2007-06-27	2014-06-12	Merck Sharp & Dohme Llc	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en)	2008-03-03	2009-09-11	Tiger Pharmatech	Tyrosine kinase inhibitors
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
AU2010247735B2 (en)	2009-05-12	2015-07-16	Albany Molecular Research, Inc.	Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
WO2010132437A1 (en)	2009-05-12	2010-11-18	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247763B2 (en)	2009-05-12	2015-12-24	Albany Molecular Research, Inc.	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
PE20121172A1 (es)	2009-10-14	2012-09-05	Merck Sharp & Dohme	Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en)	2010-06-24	2011-12-29	Merck Sharp & Dohme Corp.	Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (de)	2010-08-02	2018-06-06	Sirna Therapeutics, Inc.	Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
US9029341B2 (en)	2010-08-17	2015-05-12	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de)	2010-09-01	2016-11-02	Merck Sharp & Dohme Corp.	Indazolderivate als erk-hemmer
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en)	2010-12-21	2012-06-28	Schering Corporation	Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en)	2011-04-21	2013-10-17	Piramal Enterprises Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Neue verbindungen als erk-hemmer
US20150299696A1 (en)	2012-05-02	2015-10-22	Sirna Therapeutics, Inc.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru)	2012-09-28	2018-07-06	Мерк Шарп И Доум Корп.	Новые соединения, которые являются ингибиторами erk
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
RS56680B1 (sr)	2012-11-28	2018-03-30	Merck Sharp & Dohme	Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko)	2012-12-20	2020-12-30	머크 샤프 앤드 돔 코포레이션	Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en)	2013-09-03	2015-03-12	Moderna Therapeutics, Inc.	Circular polynucleotides
EP3525785B1 (de)	2016-10-12	2025-08-27	Merck Sharp & Dohme LLC	Kdm5-inhibitoren
EP3706747B1 (de)	2017-11-08	2025-09-03	Merck Sharp & Dohme LLC	Prmt5-inhibitoren
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
US12173026B2 (en)	2018-08-07	2024-12-24	Merck Sharp & Dohme Llc	PRMT5 inhibitors
EP3833668B1 (de)	2018-08-07	2025-03-19	Merck Sharp & Dohme LLC	Prmt5-inhibitoren

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
JPH072740B2 (ja) *	1990-06-01	1995-01-18	フアイザー・インコーポレイテツド	３―アミノ―２―アリールキヌクリジン
UA27776C2 (uk) *	1991-05-31	2000-10-16	Пфайзер Інк.	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
DE69231395T3 (de) *	1991-09-20	2005-07-21	Glaxo Group Ltd., Greenford	Neue medizinische Indikation für Tachykinin-Antagonisten
US5340826A (en) *	1993-02-04	1994-08-23	Pfizer Inc.	Pharmaceutical agents for treatment of urinary incontinence

1993
- 1993-07-19 DK DK93917176.5T patent/DK0668863T3/da active
- 1993-07-19 EP EP93917176A patent/EP0668863B1/de not_active Expired - Lifetime
- 1993-07-19 JP JP6502707A patent/JP2668164B2/ja not_active Expired - Lifetime
- 1993-07-19 DE DE69307340T patent/DE69307340T2/de not_active Expired - Fee Related
- 1993-07-19 AT AT93917176T patent/ATE147385T1/de not_active IP Right Cessation
- 1993-07-19 CA CA002149242A patent/CA2149242C/en not_active Expired - Fee Related
- 1993-07-19 WO PCT/US1993/006624 patent/WO1994011368A1/en not_active Ceased
- 1993-07-19 KR KR1019950701877A patent/KR950704311A/ko not_active Ceased
- 1993-07-19 NZ NZ254604A patent/NZ254604A/en unknown
- 1993-07-19 AU AU46780/93A patent/AU676489B2/en not_active Ceased
- 1993-07-19 ES ES93917176T patent/ES2096312T3/es not_active Expired - Lifetime
- 1993-07-19 US US08/500,958 patent/US5886009A/en not_active Expired - Fee Related
- 1993-11-04 IL IL10749593A patent/IL107495A/en not_active IP Right Cessation
- 1993-11-09 MY MYPI93002345A patent/MY130145A/en unknown
- 1993-11-11 CN CN93114371A patent/CN1034732C/zh not_active Expired - Fee Related
- 1993-11-11 MX MX9307062A patent/MX9307062A/es not_active IP Right Cessation
- 1993-11-11 FI FI934983A patent/FI934983A7/fi unknown
- 1993-11-11 ZA ZA938421A patent/ZA938421B/xx unknown
1997
- 1997-01-31 GR GR970400170T patent/GR3022459T3/el unknown

Also Published As

Publication number	Publication date
FI934983A0 (fi)	1993-11-11
DE69307340T2 (de)	1997-04-24
ES2096312T3 (es)	1997-03-01
IL107495A0 (en)	1994-02-27
ZA938421B (en)	1995-05-11
KR950704311A (ko)	1995-11-17
GR3022459T3 (en)	1997-04-30
MX9307062A (es)	1994-05-31
DK0668863T3 (da)	1997-06-30
EP0668863B1 (de)	1997-01-08
FI934983L (fi)	1994-05-13
IL107495A (en)	1998-12-27
CA2149242A1 (en)	1994-05-26
MY130145A (en)	2007-06-29
CN1091134A (zh)	1994-08-24
NZ254604A (en)	1997-06-24
AU4678093A (en)	1994-06-08
EP0668863A1 (de)	1995-08-30
CA2149242C (en)	1998-08-04
CN1034732C (zh)	1997-04-30
US5886009A (en)	1999-03-23
JP2668164B2 (ja)	1997-10-27
JPH07508731A (ja)	1995-09-28
FI934983A7 (fi)	1994-05-13
AU676489B2 (en)	1997-03-13
DE69307340D1 (de)	1997-02-20
WO1994011368A1 (en)	1994-05-26

Legal Events

Date	Code	Title	Description
1997-08-15	UEP	Publication of translation of european patent specification
2002-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE147385T1 (de)	1997-01-15	Chinuclidin derivat als substanz p antagonist
FI935134A0 (fi)	1993-11-19	Substituerade 3-aminokinuklidiner
MY107157A (en)	1995-09-30	Quinuclidine derivatives.
UA27776C2 (uk)	2000-10-16	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
CA2164689A1 (en)	1996-06-10	NK-1 Receptor Antagonists and 5HT3 Receptor Antagonists for the Treatment of Emesis
BRPI0108977B8 (pt)	2021-05-25	compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
EP1219622A3 (de)	2003-03-12	Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
SE9503924D0 (sv)	1995-11-07	Novel opioid peptides
DK0738269T5 (da)	2000-12-18	Piperidinderivater med PAF-antagonistaktivitet
DE69824313D1 (de)	2004-07-08	Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
DK0823909T3 (da)	2003-01-20	Hidtil ukendte heterocykliske forbindelser
FI954614A0 (fi)	1995-09-28	Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina
AU2287197A (en)	1997-10-22	Heterocyclic compounds and their preparation and use
NO951865L (no)	1995-05-11	Quinuclidin-derivat som substans-P antagonist
ATE232848T1 (de)	2003-03-15	Benzoesäurederivate und deren medizinische verwendung
SE9502877D0 (sv)	1995-08-18	Novel opioid peptides